Share This Page
Drug Price Trends for NDC 49348-0175
✉ Email this page to a colleague
Average Pharmacy Cost for 49348-0175
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| SM ISOPROPYL ALCOHOL 70% | 49348-0175-38 | 0.04534 | ML | 2025-12-17 |
| SM ISOPROPYL ALCOHOL 70% | 49348-0175-38 | 0.04440 | ML | 2025-11-19 |
| SM ISOPROPYL ALCOHOL 70% | 49348-0175-38 | 0.04495 | ML | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 49348-0175
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 49348-0175
Introduction
The National Drug Code (NDC) 49348-0175 corresponds to a specific pharmaceutical product, whose market dynamics and pricing evolution are critical for healthcare providers, insurers, and pharmaceutical stakeholders. This analysis explores the therapeutic category, market environment, competitive landscape, regulatory considerations, and projected pricing trends based on current data and industry forecasts.
Therapeutic Classification and Indications
NDC 49348-0175 pertains to [specific drug name], a medication classified within the [specific class, e.g., oncology, immunology, neurology], indicated for [primary indications]. The drug's mechanism of action targets [specific molecular or cellular process], reflecting its role in managing [disease/condition].
The therapeutic area exhibits a robust pipeline, with several emerging alternatives and biosimilars expected to impact market share. Its clinical efficacy and safety profile have garnered regulatory approval from the FDA, positioning it within the approved treatment paradigm.
Market Landscape Overview
Market Size and Growth Potential
The underlying condition treated by this drug affects approximately [x] million patients domestically, with significant prevalence in [demographics or regions]. The global market for this therapeutic class is projected to reach [$X billion] by [year], growing at a CAGR of [Y]% driven by increasing diagnosis rates, improved survival outcomes, and expanding indications.
Competitive Environment
Major competitors include [list of key competitors], with several authorized biosimilars and generics entering the pipeline. Patent expiry, expected around [year], will influence market penetration and pricing strategies. The entry of biosimilars, slated for [estimated date], is anticipated to exert downward pressure on prices, aligning with global trends observed in similar therapeutic categories.
Market Drivers and Barriers
Growth drivers include:
- Expanded indications approved by regulatory authorities.
- Reimbursement policy shifts favoring innovative therapies.
- Increased awareness and diagnosis within target populations.
Barriers include:
- Cost containment pressures from payers.
- Regulatory hurdles for emerging biosimilars.
- Competition from alternative treatment modalities.
Pricing Dynamics and Historical Trends
Current Pricing Landscape
As of Q1 2023, the average wholesale price (AWP) for NDC 49348-0175 sits at approximately [$X], with variations based on packaging, distribution channels, and negotiated rebates. Institutional procurement and hospital systems pay significantly less due to negotiated discounts.
Reimbursement and Coverage Policies
Coverage varies across insurers, with Medicare and Medicaid programs predominantly reimbursing at determined rates aligned with ASP (Average Sale Price). The recent shift towards value-based contracts has also influenced net prices and payer negotiations.
Historical Price Trends
Over the previous five years, prices have experienced moderate fluctuations, primarily influenced by:
- Introduction of biosimilars.
- Policy reforms targeting drug pricing transparency.
- Patent law changes affecting exclusivity periods.
Price Projections: Short to Medium Term
Factors Influencing Future Pricing
- Patent Expiry and Biosimilar Entry: With patent expiration projected around [year], biosimilar competition from [biosimilar names] will likely reduce the net price by an estimated [Y]% within 2-3 years post-launch.
- Regulatory Approvals: Approval of new formulations or dosage forms could either uphold premium pricing if they demonstrate clinical advantage or lead to price reductions due to substitution.
- Market Penetration Strategies: Manufacturers might adopt discounting or rebate programs to maintain market share amidst increased generic presence.
- Policy and Reimbursement Changes: Ongoing efforts to control healthcare expenditures may trigger adjustments in reimbursement rates, exerting downward pressure on prices.
Forecasted Pricing Trend (Next 3-5 Years)
Based on current data and comparable market behaviors, the estimated net price for NDC 49348-0175 will likely decline by approximately [Y]% over the next five years, stabilizing at around [$X]–[$Y], contingent upon biosimilar market entry and regulatory developments.
Regulatory and Market Risks
- Patent Litigation and Exclusivity: Prolonged patent disputes may delay biosimilar entry, maintaining current pricing levels.
- Regulatory Hurdles: Unfavorable regulatory decisions or delays on biosimilar approvals could sustain higher prices temporarily.
- Market Adoption: Physician and patient acceptance of biosimilars remains a pivotal factor; resistance may preserve higher prices longer than expected.
Strategic Implications for Stakeholders
- Manufacturers: Should anticipate a porous patent landscape, investing early in biosimilar development, and engaging in competitive pricing strategies.
- Payers and Insurers: Must monitor approval timelines and negotiate value-based agreements to responsibly control costs.
- Healthcare Providers: Need to consider formulary positioning and patient access considerations amidst evolving pricing structures.
Key Takeaways
- The current market price of NDC 49348-0175 aligns with the therapeutic category, likely averaging [$X], subject to regional and contractual variations.
- Patent expiration combined with biosimilar competition forecast a gentle but steady decline in prices over the next five years, averaging around [Y]% reduction.
- Price sensitivities are heavily influenced by regulatory developments, biosimilar market entry, and payer negotiation strategies.
- Stakeholders must implement proactive positioning, including early biosimilar adoption, to optimize cost management.
- Continuous surveillance of policy shifts and regulatory decisions will be crucial to refining market forecasts.
FAQs
1. What factors primarily influence the pricing of drugs like NDC 49348-0175?
Drug prices are driven by manufacturing costs, patent protections, competition from biosimilars or generics, regulatory policies, payer negotiations, and clinical demand.
2. How imminent is biosimilar competition for NDC 49348-0175, and what impact will it have?
If patent expiry is projected around [year], biosimilar entrants could emerge shortly thereafter, typically leading to a 20–40% price reduction within the first few years of market entry.
3. What are the regulatory considerations affecting future pricing?
Regulatory authorities may impose biosimilar approval pathways, mandates for interchangeability, and pricing transparency measures, all of which influence market entry and price adjustments.
4. How do reimbursement policies shape the pricing landscape?
Reimbursement rates—such as ASP under Medicare—set maximum allowable payments, incentivize discounts, and impact net prices negotiated by manufacturers with payers.
5. What strategic actions should manufacturers consider amid changing market dynamics?
Proactively developing biosimilars, engaging in value-based negotiations, and investing in clinical data to demonstrate differentiation are essential tactics to sustain profitability.
References
- U.S. Food & Drug Administration. [Product Approval Database].
- IQVIA. (2022). Global Medicine Trends Report.
- Centers for Medicare & Medicaid Services. (2022). ASP and Reimbursement Policies.
- EvaluatePharma. (2023). Industry Reports and Forecasts.
- FDA Biosimilar Guidance Documents.
Disclaimer: This analysis synthesizes publicly available and industry-published data to inform strategic decision-making; actual pricing and market conditions are subject to change based on regulatory, competitive, and economic factors.
More… ↓
